SAN DIEGO (September 24, 2021)—Cue Health Inc., a health technology company, announced the pricing of its initial public offering of 12,500,000 shares of its common stock at a public offering price of $16.00 per share, for gross proceeds of $200.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by Cue Health. All of the shares are being offered and sold by Cue Health.
Cue Health's common stock is expected to begin trading on the Nasdaq Global Select Market on Sept. 24, 2021 under the ticker symbol "HLTH." The offering is expected to close on Sept. 28, 2021, subject to the satisfaction of customary closing conditions. In addition, Cue Health has granted the underwriters a 30-day option to purchase up to 1,875,000 additional shares of common stock at the initial public offering price, less the underwriting discounts and commissions.
Goldman Sachs & Co. LLC, Morgan Stanley & Co. LLC, and Cowen and Company, LLC are acting as lead bookrunners for the offering. BTIG, LLC is acting as lead manager for the offering.
A registration statement relating to the offering of these securities was declared effective by the Securities and Exchange Commission (SEC) on Sept. 23, 2021. Copies of the registration statement can be accessed by visiting the SEC website at sec.gov. The securities referred to in this release are to be offered only by means of a prospectus. A preliminary prospectus describing the terms of the offering has been filed with the SEC and forms a part of the effective registration statement. When available, a copy of the final prospectus relating to the offering may be obtained from:
Goldman Sachs & Co. LLC,
Attention: Prospectus Department
200 West Street
New York, NY 10282
(866) 471-2526
prospectus-ny@ny.email.gs.com
Morgan Stanley & Co. LLC
Attention: Prospectus Department
180 Varick Street, 2nd Floor
New York, NY 10014
prospectus@morganstanley.com
Cowen and Company, LLC, c/o Broadridge Financial Solutions
1155 Long Island Avenue
Edgewood, NY 11717
Attn: Prospectus Department
(833) 297-2926
postsalemanualrequests@broadridge.com
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
Visit cuehealth.com for more information.
